Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists
First Claim
1. A method for treating sexual dysfunction in a female individual caused by lack of increased blood flow in the female individual'"'"'s genitalia in response to sexual stimulation, comprising administering to the vagina and/or vulvar region of the individual a pharmaceutical formulation that comprises an amount of a vasoactive intestinal polypeptide (VIP) agonist sufficient to cause increased blood flow in the female individual'"'"'s genitalia, wherein the vasoactive intestinal polypeptide agonist is selected from SEQ ID NOs:
- 204–
206.
0 Assignments
0 Petitions
Accused Products
Abstract
Methods for treating female sexual dysfunction are provided. A pharmaceutical composition containing a vasoactive agent selected from vasoactive intestinal potypeptide (VIP) and VIP agonists is administered to the vagina and/or vulvar region of the individual undergoing treatment. The formulations are also useful for improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. Pharmaceutical formulations and kits are also provided.
-
Citations
23 Claims
- 1. A method for treating sexual dysfunction in a female individual caused by lack of increased blood flow in the female individual'"'"'s genitalia in response to sexual stimulation, comprising administering to the vagina and/or vulvar region of the individual a pharmaceutical formulation that comprises an amount of a vasoactive intestinal polypeptide (VIP) agonist sufficient to cause increased blood flow in the female individual'"'"'s genitalia, wherein the vasoactive intestinal polypeptide agonist is selected from SEQ ID NOs:
-
20. A method for maintaining the health of healthy tissue, or improving the health of unhealthy tissue of the female genitalia, comprising administering to a female individual, on an as-needed basis, a therapeutically effective amount of a vasoactive intestinal polypeptide agonist selected from SEQ ID NOs:
- 204–
206.
- 204–
-
21. A method for decreasing vaginal atrophy, comprising administering to a female individual, on an as-needed basis, a therapeutically effective amount of a vasoactive intestinal polypeptide agonist selected from SEQ ID NOs:
- 204–
206.
- 204–
-
22. A method for decreasing vaginal pain caused by dyspareunia during sexual intercourse, comprising administering to a female individual suffering from dyspareunia a therapeutically effective amount of a vasoactive intestinal polypeptide agonist selected from SEQ ID NOs:
- 204–
206.
- 204–
-
23. A method for alleviating vaginal itching and dryness, comprising administering to a female individual in need of such treatment a therapeutically effective amount of a vasoactive intestinal polypeptide agonist selected from SEQ ID NOs:
- 204–
206 on an as-needed basis.
- 204–
Specification